Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-T2D
NCT03620773Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Oct 2018
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Colorado Denver. Primary endpoints: Pancreatic β-cell function at 4 hours, Effective Renal Plasma Flow at 4 hours and 1 more. Started Oct 2018; status: completed.
Beyond the preview
Go deeper on NCT03620773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620773.